Stockscreener 앱 받기
18.80
4.16%
0.75
전일 마감가:
$18.05
열려 있는:
$18.12
하루 거래량:
91,523
Relative Volume:
0.70
시가총액:
$702.75M
수익:
$239.40M
순이익/손실:
$104.44M
주가수익비율:
-7.2868
EPS:
-2.58
순현금흐름:
$-18.50M
1주 성능:
+5.32%
1개월 성능:
+9.75%
6개월 성능:
+17.43%
1년 성능:
+65.49%
1일 변동 폭
$17.90
$18.95
1주일 범위
$17.09
$18.95
52주 변동 폭
$10.95
$20.49
Entrada Therapeutics Inc Stock (TRDA) Company Profile
명칭
Entrada Therapeutics Inc
전화
857-305-1825
주소
ONE DESIGN CENTER PLACE, BOSTON
TRDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| TRDA | 18.80 | 702.75M | 239.40M | 104.44M | -18.50M | -2.58 |
| VRTX | 450.97 | 116.38B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 82.09B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.14B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.25B | 3.30B | -501.07M | 1.03B | 11.54 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-05 | 개시 | Oppenheimer | Outperform |
| 2023-04-03 | 개시 | H.C. Wainwright | Buy |
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
Los Angeles Capital Management LLC Makes New $542,000 Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Insider Sale at Entrada Therapeutics Inc (TRDA) by President of Research & Development - GuruFocus.com
500: Something went wrong - Investing.com UK
Entrada Therapeutics stock hits 52-week high at $20.28 By Investing.com - Investing.com Canada
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates - MSN
HC Wainwright Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - Defense World
HC Wainwright Analysts Boost Earnings Estimates for TRDA - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Entrada Therapeutics president sells shares worth $339,280 By Investing.com - Investing.com Australia
Equities Analysts Issue Forecasts for TRDA FY2024 Earnings - MarketBeat
HC Wainwright Has Positive Outlook of TRDA FY2024 Earnings - MarketBeat
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock - Benzinga
Oppenheimer Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - MarketBeat
Entrada Therapeutics stock target increased on positive trial data By Investing.com - Investing.com UK
Entrada Therapeutics (NASDAQ:TRDA) Price Target Raised to $20.00 - MarketBeat
Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Entrada Therapeutics’ Q3 2024 Financial Highlights - TipRanks
Entrada Therapeutics (NASDAQ:TRDA) Hits New 12-Month HighHere's What Happened - MarketBeat
Entrada Therapeutics stock hits 52-week high at $18.22 By Investing.com - Investing.com UK
Entrada Therapeutics : Corporate Presentation - Marketscreener.com
Entrada Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Here's Why Momentum in Entrada Therapeutics (TRDA) Should Keep going - MSN
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Short Interest Down 19.1% in October - MarketBeat
Short Interest in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Declines By 19.1% - Defense World
Here's What Could Help Entrada Therapeutics (TRDA) Maintain Its Recent Price Strength - MSN
Entrada Therapeutics president sells $10,800 in stock By Investing.com - Investing.com Australia
Natarajan Sethuraman Sells 600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock - MarketBeat
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding - Simply Wall St
Oppenheimer Initiates Coverage of Entrada Therapeutics (TRDA) with Outperform Recommendation - MSN
(TRDA) Trading Report - Stock Traders Daily
The Manufacturers Life Insurance Company Purchases 2,146 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Renaissance Technologies LLC Invests $636,000 in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics advances Duchenne treatment trials - Investing.com
Entrada Therapeutics advances Duchenne treatment trials By Investing.com - Investing.com UK
Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society - The Manila Times
HRMY: 3 Small-Cap Biotech Stocks to Buy for Major Upside - StockNews.com
(TRDA) Trading Advice - Stock Traders Daily
Morguard Un (MRT-UN-T) QuotePress Release - The Globe and Mail
Pompe Disease Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Market Dynamics, MOA, ROA by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas - The Globe and Mail
Entrada Therapeutics COO sells shares worth over $13,000 - Investing.com India
Entrada Therapeutics COO sells shares worth over $13,000 By Investing.com - Investing.com Australia
Insider Sale: President & COO Nathan Dowden Sells Shares of Entr - GuruFocus.com
Entrada Therapeutics (NASDAQ:TRDA) Trading 4.8% Higher - MarketBeat
U.S. Gold Corp (USAU-Q) QuotePress Release - The Globe and Mail
Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development - Markets Insider
Entrada Therapeutics appoints new President of R&D - Investing.com
Entrada Therapeutics Inc (TRDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):